Crestor's Profile, Price Make It Best Value Among Statins, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Crestor is the "most economical option," the company tells investors. Rhabdomyolysis reports hurt the product launch, but AstraZeneca now expects a "strong drive" toward its goal of capturing 20% market share.
You may also be interested in...
Public Citizen Challenges Timing Of AstraZeneca Crestor Adverse Event Reports
AstraZeneca "illegally" delayed the submission of 23 cases of serious adverse drug reactions by including them in quarterly reports rather than submitting them on an expedited basis, Public Citizen says. AstraZeneca maintains that rhabdomyolysis and renal failure are labeled events that do not require 15-day alert reports.
Merck/Schering's Vytorin Clears FDA
Zetia/Zocor fixed-dose combination will be marketed as a first-line therapy for cholesterol.
AstraZeneca Questions Reliability Of Crestor Adverse Event Reports
A Public Citizen petition seeking withdrawal of rosuvastatin is “based on inappropriate and misleading interpretations of selective and incomplete data,” CEO McKillop says. AstraZeneca asserts Crestor’s adverse event profile is similar to other statins.